Head & neck · 2014
Prognostic factors for squamous cell cancer of the parotid gland: an analysis of 2104 patients.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chen Michelle M, Roman Sanziana A, Sosa Julie A, Judson Benjamin L
Аннотация
BACKGROUND: Parotid gland squamous cell cancer (SCC) occurs as metastasis from cutaneous SCC or primary malignancy. There is limited data on incidence, prognosis, and treatment outcomes.
METHODS: The Surveillance, Epidemiology, and End Results (SEER) database (1988-2009) identified 2104 adult patients with parotid SCC.
RESULTS: SCC is the second most common parotid malignancy, and its incidence is increasing (annual percentage change 1.7%; ptrend = .004). Age ≥85 years, tumor size ≥4 cm, extraparenchymal extension, cervical metastases, and distant metastases were independently associated with disease-specific mortality. Compared to no surgery, surgery was associated with improved 5-year disease-specific survival (DSS; 44.4% vs 71.0%; p < .001), whereas radiation alone was similar to no treatment (47.0% vs 41.6%; p = .28).
CONCLUSION: Surgery and adjuvant radiation therapy (RT) are associated with improved survival compared to radiation alone and no treatment. Patients ≥85 years of age account for nearly 20% of all patients and have a poor prognosis independent of treatment.
METHODS: The Surveillance, Epidemiology, and End Results (SEER) database (1988-2009) identified 2104 adult patients with parotid SCC.
RESULTS: SCC is the second most common parotid malignancy, and its incidence is increasing (annual percentage change 1.7%; ptrend = .004). Age ≥85 years, tumor size ≥4 cm, extraparenchymal extension, cervical metastases, and distant metastases were independently associated with disease-specific mortality. Compared to no surgery, surgery was associated with improved 5-year disease-specific survival (DSS; 44.4% vs 71.0%; p < .001), whereas radiation alone was similar to no treatment (47.0% vs 41.6%; p = .28).
CONCLUSION: Surgery and adjuvant radiation therapy (RT) are associated with improved survival compared to radiation alone and no treatment. Patients ≥85 years of age account for nearly 20% of all patients and have a poor prognosis independent of treatment.